Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Significance: The development of acquired chemoresistance is often a clinical problem limiting the successful treatment of cancers. RNAi is showing promising results in human clinical trials. The combination of chemotherapy with RNAi approaches to suppress the expression of proteins involved in the emergence of drug resistance represents a promising synergistic strategy to circumvent or reverse acquired chemoresistance. Such combination therapy approaches require specific delivery vehicles to encapsulate and deliver chemotherapy and siRNA therapeutics simultaneously in a controlled manner. Herein, we describe a nanoparticle technology to codeliver a DNA-damaging chemotherapeutic and siRNAs that impair the cell’s ability to repair the DNA damage. This combination therapeutic approach can sensitize cancer cells to chemotherapeutics and shows superior tumor inhibition compared with monochemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“nanoparticle-based preclinical studies in which TLS polymerases were targeted with siRNA in combination with cisplatin [123] also indicated that TLS inhibition mediated by PIP box peptides or novel drugs may pave avenues towards the improvement of cancer treatments.”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 2×
“available in the cell? Chem Rev 99(9):2499–2510.”
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348 · cited 1×
“Similarly, the methods by which chemotherapeutics are delivered also have a significant effect on the efficacy (16, 17).”
Self-citationKnocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · cited 1×
“Naked siRNA cannot readily cross cellular membranes due to its polyanionic and macromolecular characteristics, and it is susceptible to degradation by endogenous enzymes (12).”
Self-citationEvidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147 · cited 1×
“Recently, a docetaxel-containing formulation termed BIND014 (BIND Biosciences), which has been selected from an NP library composed of poly(D,L-lactide), PLGA, and PEG, is currently in phase I clinical trials (24).”
Self-citationMechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969 · cited 3×
“In contrast, PLGA-PEG NPs were only able to encapsulate ∼6–10% of the initial siRNA, suggesting that G0C14 drastically enhanced the entrapment of siRNA within NPs.”
InfluentialSelf-citationWhy Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Reedijk, J. (1999) · Chemical Reviews · doi:10.1021/cr980422f · Cited by 771 · cited 1×
“Another possible explanation is that NPs shield compound 1 from unspecific interactions with albumin present in the cell growth medium, which are considered to be the main route for platinum binding in human blood plasma (32).”
Wang, Y., Gao, S., Ye, W.-H., Yoon, H. S., & Yang, Y.-Y. (2006) · Nature Materials · doi:10.1038/nmat1737 · Cited by 658 · cited 1×
“Recent research has begun to explore the feasibility of combining chemotherapeutics with siRNA using a variety of nanocarrier platforms (18, 19).”
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565 · cited 1×
“(25) for codelivery of cisplatin and docetaxel, two drugs with different characteristics and metabolic targets, to prostate cancer cells.”
Self-citation
Research works printed but not linked: 1
- Ryan CJ (2013) Clinical trial design strategies in the post-abiraterone/enzalutamide setting. 2013 Genitourinary Cancers Symposium Proceedings ed Carducci MA (American Society of Clinical Oncology Alexandria VA) pp 26–28.
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
“This synergy has been demonstrated for combinations of small molecular weight drugs in vitro [21], combinations of a cisplatin prodrug and siRNA in vivo [22] or the combination of siRNA targeting 2 different genes in humans [3], highlighting the potential of encapsulating multiple API in a single carrier.”
BackgroundSelf-citationMechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039
“Interestingly, the TLS polymerases, REV1 and REV3, were also implicated in the development of chemoresistance in human cells and mice models, opening the possibility for a whole new class of promising chemotherapeutic drugs [Doles et al., 2010; Xie et al., 2010; Xu et al., 2013].”
Self-citationHe, C., Liu, D., & Lin, W. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00125 · Cited by 1,001
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
“Recently, a polymeric NP platform composed of an aqueous inner core, a cationic and hydrophobic PLGA layer, and a hydrophilic PEG corona was developed to circumvent acquired chemoresistance by simultaneously delivering a cisplatin prodrug and REV1/REV3L-specific siRNAs, which suppress gene targets crucial to translesi…”
BackgroundSelf-citation
Metadata
- Authors
- Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., Langer, R., Walker, G. C., & Farokhzad, O. C.
- Affiliations
- Brigham and Women's Hospital (US)
- Northwestern University (US)
- Massachusetts Institute of Technology (US)
- Harvard University (US)
- The David H. Koch Institute for Integrative Cancer Research and
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-10-28
- Volume
- 110
- Issue
- 46
- Pages
- 18638-18643
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3832000
- OpenAlex
- W2158787062
- Cited by
- 340
- References
- 32
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 18 · 2023: 23 · 2022: 27 · 2021: 37 · 2020: 33 · 2019: 25 · 2018: 26 · 2017: 31 · 2016: 32 · 2015: 44 · 2014: 17 · 2013: 2
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- National Cancer Institute (F32CA168163, R00CA160350, U54CA151884, CA151884, K99CA160350, R01CA034992)
- National Institute of Environmental Health Sciences (ES-015818, R56ES015818, R01ES015818)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- cisplatin prodrug, siRNA delivery, nanoparticle drug delivery, co-delivery, translesion synthesis, Rev1, REV3L, acquired chemoresistance, DNA-damaging chemotherapy, synergistic antitumor effect, siRNA knockdown
- MeSH terms
- Antineoplastic Agents, Cisplatin, Drug Carriers, Drug Therapy, Combination, Humans, Luciferases, Platinum, Drug Delivery Systems, Drug Resistance, Neoplasm, Gene Silencing, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. https://app.cochat.ai/papers/10.1073/pnas.1303958110
- The paper
- Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., Langer, R., Walker, G. C., & Farokhzad, O. C. (2013). Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1303958110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.